Anti Epileptic Drug News and Research

RSS

Can cannabis help curb convulsions?

Experts say that vigorous investigations are needed to determine whether or not the medical use of marijuana would be of benefit to patients with epilepsy.

22 May 2014

NYU Langone Medical Center implants RNS device in brain for patients with epilepsy

NYU Langone Medical Center last month became the first hospital outside of a clinical trial site to implant a pacemaker-like device in the brain that may be a game-changer for patients with epilepsy.

22 May 2014

Eisai launches new class of epilepsy treatment Fycompa in France

Fycompa (perampanel), the first in an entirely new class of treatment for partial onset seizures (the most common form of epilepsy), has today received reimbursement approval from the Comité Economique des Produits de Santé.

22 May 2014

Autoimmune epilepsy diagnostics: an interview with Dr. Joseph J. Higgins, Medical Director, Neurology, Athena Diagnostics, a business of Quest Diagnostics

Epilepsy is a group of neurological disorders often characterized by seizures and cognitive impairment due to electrical disturbances in the brain.

From Quest Diagnostics 14 May 2014

Ligand's total revenues increase 37% to $16.0 million in first quarter 2014

Ligand Pharmaceuticals Incorporated today reported financial results for the three months ended March 31, 2014, and provided an operating forecast and program updates.

7 May 2014

Acorda gets FDA Complete Response Letter for PLUMIAZ Nasal Spray NDA

Acorda Therapeutics, Inc. today announced that the U.S. Food and Drug Administration has issued a Complete Response Letter (CRL) for the New Drug Application (NDA) for PLUMIAZ (diazepam) Nasal Spray for the treatment of people with epilepsy who experience cluster seizures.

2 May 2014

Scientists find key information that may lead to new therapeutic approaches to epilepsy

A team of researchers from Sanford-Burnham Medical Research Institute (Sanford-Burnham) and SUNY Downstate Medical Center (SUNY Downstate) has found that deficiencies in hyaluronan, also known as hyaluronic acid or HA, can lead to spontaneous epileptic seizures.

2 May 2014

Experts create new definition for epilepsy

An expert task force has created a new definition for epilepsy that refines the scope of patients diagnosed with this brain disease. The study published in Epilepsia, a journal published by Wiley on behalf of the International League Against Epilepsy, provides a greater level of detail to diagnose epilepsy by including individuals with two unprovoked seizures, and those with one unprovoked seizure and other factors that increase risk of seizure recurrence.

15 Apr 2014

SAGE Therapeutics doses first patient in SAGE-547 Phase 1/2 trial for treatment of SRSE

SAGE Therapeutics, a biopharmaceutical company developing novel medicines to treat life-threatening and rare central nervous system (CNS) disorders, today announced dose initiation of the first patient in a Phase 1/2 clinical trial of SAGE-547, a neuroactive steroid, in super-refractory status epilepticus (SRSE), a critical condition in which the brain is in a state of persistent seizure.

27 Mar 2014

FDA accepts Lundbeck's carbamazepine NDA for review

Lundbeck LLC today announced that the U.S. Food and Drug Administration has accepted for review a New Drug Application (NDA) for its investigational therapy intravenous carbamazepine, an intravenous formulation of the anti-epileptic drug (AED) carbamazepine. An action letter is anticipated before the end of 2014. Carbella is the proposed U.S. trade name for intravenous carbamazepine.

10 Mar 2014

Children with FSE who receive earlier treatment with AEDs experience reduction in duration of seizure

New research shows that children with febrile status epilepticus (FSE) who receive earlier treatment with antiepileptic drugs (AEDs) experience a reduction in the duration of the seizure.

6 Feb 2014

UCSF-led study gathers data on safety, tolerability of purified cannabinoid for children with epilepsy

A new international multi-center study led by researchers from UCSF Benioff Children's Hospital is the first to evaluate whether purified cannabinoid is effective in treating severe forms of childhood epilepsy that do not respond to standard antiepileptic drugs.

5 Feb 2014

Researchers discover new gene involved in severe childhood epilepsy

A European consortium of epilepsy researchers has reported the discovery of a new gene involved in severe childhood epilepsy. Using a novel combination of technologies, including trio exome sequencing of patient/parental DNA and genetic studies in the tiny larvae of zebrafish, the EuroEPINOMICS RES consortium found that mutations in the gene CHD2 are responsible for a subset of epilepsy patients with symptoms similar to Dravet syndrome - a severe form of childhood epilepsy that is in many patients resistant to currently available anti-epileptic drugs.

23 Jan 2014

Biosimulation and epilepsy treatments: an interview with Dr. Serge Bischoff, CEO of Rhenovia and RHENEPI program director

The need for biosimulation is primarily to do with the very high attrition rate in drug development and especially in the development of drugs for the central nervous system.

10 Dec 2013

Epilepsy experts discuss on new NTI definition, bioequivalence guidelines at AES annual meeting

For several years, epilepsy practitioners have questioned the U.S. Food and Drug Administration's definition of bioequivalence as it applies to narrow therapeutic index drugs, such as those used for epilepsy. In response to these concerns, the FDA has sponsored 3 studies of antiepileptic drugs and also convened an advisory board to help determine which drugs are NTI.

10 Dec 2013

Studies expose high prevalence of epilepsy and other neurological disorders in US Veterans

Three studies coming out of the American Epilepsy Society's 67th Annual Meeting in Washington DC expose the high prevalence of epilepsy and other neurological disorders in US Veterans who served in Operation Enduring Freedom, Operation Iraqi Freedom and Operation New Dawn. The research conducted from these studies indicate that veterans are at a particularly high risk for traumatic brain injury, post traumatic stress disorder, psychological non-epileptic seizures and epileptic seizure diagnoses.

10 Dec 2013

Study demonstrates feasibility to detect generalized tonic-clonic seizures with arm device

Medications remain the mainstay of epilepsy treatment, and to date there are no FDA-approved devices that provide an accurate means of detection for generalized tonic-clonic seizures, or convulsions, during activities of daily living. Two new studies presented at the American Epilepsy Society's 67th Annual Meeting in Washington D.C. provide data that warrants the development of non-invasive devices with the capability to signal the onset of an epileptic seizure and could be crucial to optimal patient dosing.

10 Dec 2013

New findings on effects of epilepsy on mother and child

New research pertaining to the latest findings on the effects of epilepsy on both the mother and child were presented at the American Epilepsy Society's 67th Annual Meeting in Washington DC. These studies explore folic acid use, the effect of surgery with intractable focal epilepsy, and antiepileptic drug exposure during breastfeeding.

10 Dec 2013

Study: Uncontrolled epilepsy associated with higher healthcare utilization

Seizures in people with epilepsy are commonly treated with anti-epileptic drugs (AEDs) but 30-40 percent do not achieve adequate seizure control, predisposing them to severe health risks, impaired quality of life and higher healthcare costs.

9 Dec 2013

Eisai reports new data analyses on FYCOMPA (Perampanel) at AES meeting

Today, Eisai Inc. announced that 16 abstracts highlighting new data analyses on FYCOMPA (perampanel) will be presented at the 67th annual American Epilepsy Society (AES) meeting, taking place in Washington, D.C. from December 6 – 10.

6 Dec 2013

Anti Epileptic Drug News and Research

Can cannabis help curb convulsions?

NYU Langone Medical Center implants RNS device in brain for patients with epilepsy

Eisai launches new class of epilepsy treatment Fycompa in France

Autoimmune epilepsy diagnostics: an interview with Dr. Joseph J. Higgins, Medical Director, Neurology, Athena Diagnostics, a business of Quest Diagnostics

Ligand's total revenues increase 37% to $16.0 million in first quarter 2014

Acorda gets FDA Complete Response Letter for PLUMIAZ Nasal Spray NDA

Scientists find key information that may lead to new therapeutic approaches to epilepsy

Experts create new definition for epilepsy

SAGE Therapeutics doses first patient in SAGE-547 Phase 1/2 trial for treatment of SRSE

FDA accepts Lundbeck's carbamazepine NDA for review

Children with FSE who receive earlier treatment with AEDs experience reduction in duration of seizure

UCSF-led study gathers data on safety, tolerability of purified cannabinoid for children with epilepsy

Researchers discover new gene involved in severe childhood epilepsy

Biosimulation and epilepsy treatments: an interview with Dr. Serge Bischoff, CEO of Rhenovia and RHENEPI program director

Epilepsy experts discuss on new NTI definition, bioequivalence guidelines at AES annual meeting

Studies expose high prevalence of epilepsy and other neurological disorders in US Veterans

Study demonstrates feasibility to detect generalized tonic-clonic seizures with arm device

New findings on effects of epilepsy on mother and child

Study: Uncontrolled epilepsy associated with higher healthcare utilization

Eisai reports new data analyses on FYCOMPA (Perampanel) at AES meeting

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News